(2025). Platelet-Rich Plasma in Treatment of Idiopathic Carpal Tunnel Syndrome. The Egyptian Journal of Hospital Medicine, 100(1), 3747-3753. doi: 10.21608/ejhm.2025.448753
. "Platelet-Rich Plasma in Treatment of Idiopathic Carpal Tunnel Syndrome". The Egyptian Journal of Hospital Medicine, 100, 1, 2025, 3747-3753. doi: 10.21608/ejhm.2025.448753
(2025). 'Platelet-Rich Plasma in Treatment of Idiopathic Carpal Tunnel Syndrome', The Egyptian Journal of Hospital Medicine, 100(1), pp. 3747-3753. doi: 10.21608/ejhm.2025.448753
Platelet-Rich Plasma in Treatment of Idiopathic Carpal Tunnel Syndrome. The Egyptian Journal of Hospital Medicine, 2025; 100(1): 3747-3753. doi: 10.21608/ejhm.2025.448753
Platelet-Rich Plasma in Treatment of Idiopathic Carpal Tunnel Syndrome
Background: Carpal tunnel syndrome (CTS) is the most common debilitating disorder affecting the upper extremities. Platelet-rich plasma (PRP) is an emerging injectable therapy derived from the patient’s own blood, containing a higher platelet concentration than whole blood. By delivering growth factors autologously, PRP may promote peripheral nerve regeneration. Objectives:This study aimed to evaluate the efficacy of wrist-administered platelet-rich plasma (PRP) injections in the management of idiopathic carpal tunnel syndrome, and to measure outcomes by using the Visual Analogue Scale (VAS), the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), and nerve conduction studies (NCS). Patients and Methods: Twenty patients with idiopathic carpal tunnel syndrome who received PRP injections as treatment were included in this study. All patients underwent laboratory testing, imaging to rule out secondary causes, and electrophysiological testing in the form of median nerve conduction investigations. All patients were assessed before treatment and three months after the injection using the BCTQ, VAS score, and Nerve Conduction Studies (NCS) for the median nerve. Results: Three months after PRP injection, there was a highly significant improvement in median sensory conduction velocity, median sensory peak latency, and comparative median and ulnar sensory latency at the ring finger. Three months after local PRP injection, there was a notable improvement in the VAS, symptoms severity score, and function disability score. Conclusion:A single wrist-administered PRP injection is an effective treatment for CTS, reducing symptom severity and improving patients’ functional status.
View on SCiNiTO
Top